• The data shows that a specific signal detected by the fiber optic sensor can differentiate the patients with elevated filing pressure.

• The vibration shows moderate correation with Echo index E/e', which is usually use to estimate filling pressure.

• This study demonstrates the feasibility of using our sensor technology to assess filing pressure in the future.

 >Read publication

• Echocardiography is the best current non-invasive tool for diagnosing elevated filling pressure.

• The data in this initial study show a high agreement rate between the NIFP device and echocardiography result.

• Using 18mmHg as cut-off value, the agreement rate is 83%, with 74% positive agreement rate and 86% negative agreement rate, p<0.0001. N=158.

>Read publication

• The Swan-Ganz(SG) catheter is the gold standard.

• The data demonstrate that the NIFP device presents good accuracy compared to gold standard.

• Using 18mmHg as cut-off value, the accuracy is 88%, with 71% sensitivity and 91% specificity, P<0.001. N=93.

• Accuracy and correlation better than state of the art non-invasive surrogate tools.

• It is promising evidence that the NIFP device can be used to diagnose elevated filling pressure.

>Read publication

• We conducted NIFP measurements in 74 patients before or after RHC. The correlation between recorded factors and PAWP values was examined. 

• We tested NIFP‘s performance as a predictive tool for PAWP using different thresholds 15mmHg and18mmHg.

• NIFP demonstrated moderate accuracy in predicting PAWP values (all AUC > 0.75), particularly among patients without arrhythmia [AUC for Model 1 (PAWP >15): 0.80; AUC for Model 2 (PAWP >18): 0.85].

>Read publication

• In current clinical practice, physicians use a combination of examination results to diagnose elevated filling pressure. 

• This evidence demonstrates that the NIFP device can provide diagnostic results consistent with physicians’ real-world practices.

• The NIFP reading is higher in the acute condition patient group and significantly lower when patients are in a stable condition. The gap is distinct, allowing for clear differentiation between each group.

• The device successfully differentiated between chronic and acute heart failure patients, with an AUROC of 0.874 (N = 135, p < 0.001).